Scientists with the U.S. Department of Energy’s Lawrence Berkeley National Laboratory have developed a way to study the impact of spatial patterns on living cells.
Neovacs announced promising results achieved in the first 24 rheumatoid arthritis patients included in the Phase 2a study conducted with TNF-Kinoid.
Infinity Pharmaceuticals Inc. has initiated two Phase 1 clinical trials of IPI-145, a potent, orally available inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma.
The U.S. Food and Drug Administration announced the award of $2 million to support two regional Centers of Excellence in Regulatory Science and Innovation.
Spherix Inc. announced that SPX-106T reduced dyslipidemia in studies of apolipoprotein E-deficient mice and Syrian Golden hamsters.
Domainex Ltd. was awarded a $400,000 (£250,000) grant by the Technology Strategy Board to support the development of a new drug for the treatment of several common cancers.
A study by two University of Illinois at Chicago biologists finds a link that the nerve signaling inhibitor, tomosyn, may help retain long-term memory.
Biotage has introduced the Isolera Prime flash purification system. The system is upgradeable and can be expanding according to the needs of developing companies and academic institutions.
Working at a rate of over 1000 measurements per second, the Cell Tester from World Precision Instruments Inc employs state-of-the-art optics, nanopositioning and force sensor technology to deliver sensitive, robust, and reproducible force measurements.
Cobra Biologics, an international manufacturer of biopharmaceuticals, has acquired Unitech Pharma Group and its bio-production facility in Matfors, Sweden.
Auxilium Pharmaceuticals Inc. reported a narrower third-quarter loss as its sales increased. Auxilium said it lost $4.1 million; a year ago the company took a larger loss of $12.8 million.
Nuron Biotech Inc. announced the initiation of a randomized, double-blind, placebo-controlled Phase 3 study to evaluate the safety and efficacy of NU100 in patients with relapsing remitting multiple sclerosis.
Intellipharmaceutics International Inc. announced the U.S. Food and Drug Administration has accepted for filing its abbreviated new drug application for a generic version of Lamictal XR, an anticonvulsant drug used in the treatment of epilepsy.
Neurocrine Biosciences Inc. said that third-quarter jumped sharply as revenue nearly tripled as the company recognized $30 million in revenue for moving a new drug closer to regulatory approval.
Two chemicals considered harmful to babies remain in Johnson & Johnson's baby shampoo sold in the U.S. and some other countries, even though the company already makes versions without them.